---
aliases: [PFE]
---
#actor #company #pharma #healthcare #usa #public

**Pfizer** — Global pharma giant. NYSE: PFE. COVID vaccine success now fading. Navigating patent cliff with M&A.

---

## Why Pfizer matters

| Metric | Value |
|--------|-------|
| Ticker | PFE (NYSE) |
| Market cap | ~$150B |
| Revenue | ~$58B |
| R&D spend | ~$10B |
| Employees | 80K+ |
| HQ | New York |

One of world's largest pharma companies.

---

## COVID impact

| Year | COVID revenue | Total revenue |
|------|---------------|---------------|
| 2021 | $37B | $81B |
| 2022 | $57B | $100B |
| 2023 | $12B | $58B |
| 2024 | ~$5B | ~$60B |

COVID was unprecedented windfall, now normalizing.

---

## Key products

| Product | Category | Revenue |
|---------|----------|---------|
| Comirnaty | COVID vaccine | Declining |
| Paxlovid | COVID treatment | Declining |
| Eliquis | Blood thinner | ~$6B (shared) |
| Prevnar | Pneumonia vaccine | ~$6B |
| Ibrance | Breast cancer | ~$5B |
| Vyndaqel | Heart disease | Growing |

---

## Patent cliff exposure

| Drug | Patent expiry | Peak revenue |
|------|---------------|--------------|
| Eliquis | 2026-2028 | $6B+ |
| Ibrance | 2027 | $5B |
| Xtandi | 2027 | $2B |

Major revenue at risk from generics.

---

## Pipeline priorities

| Area | Approach |
|------|----------|
| Oncology | Seagen acquisition |
| Vaccines | RSV, flu combinations |
| Rare disease | Bolt-on M&A |
| GLP-1/Obesity | Late entrant |

---

## M&A strategy

| Deal | Value | Rationale |
|------|-------|-----------|
| Seagen (2023) | $43B | Oncology pipeline |
| Arena (2022) | $6.7B | Immunology |
| Biohaven (2022) | $12B | Migraine |

Using COVID cash for pipeline acquisitions.

---

## Key metrics

| Metric | Value |
|--------|-------|
| Dividend yield | ~6% |
| Payout ratio | High |
| Debt | ~$60B (post-Seagen) |
| FCF | ~$10B |

---

## Management

| Person | Role | Since |
|--------|------|-------|
| Albert Bourla | CEO | 2019 |
| David Denton | CFO | 2022 |

Bourla led COVID response, now managing transition.

---

## Investment thesis

**Bull:**
- Dividend yield attractive (~6%)
- Seagen oncology pipeline
- Vaccine franchise strength
- M&A optionality
- Valuation reset complete
- COVID learnings

**Bear:**
- Patent cliff looming
- COVID revenue collapsed
- GLP-1 late to market
- Debt from acquisitions
- Pipeline execution risk
- Biotech competition

---

## GLP-1/Obesity challenge

| Factor | Status |
|--------|--------|
| Current position | No approved product |
| Pipeline | Danuglipron (oral) discontinued |
| Competition | Lilly, Novo years ahead |
| Strategy | Exploring options |

Missing the GLP-1 wave is significant.

---

## Competitive position

| vs. Competitor | Pfizer position |
|----------------|-----------------|
| [[Eli Lilly]] | Behind in GLP-1 |
| [[Merck]] | Peer in oncology |
| [[J&J]] | Diversified peer |
| [[AbbVie]] | Peer in immunology |

---

## Related

### Competitors
- [[Eli Lilly]] — GLP-1 leader
- [[Merck]] — pharma peer
- [[Moderna]] — vaccine competitor

### Sectors
- [[Healthcare]] — industry
- [[Biotech]] — pipeline competition

### Concepts
- [[AI drug discovery]] — R&D application

---

*Updated 2026-01-16*
